tiprankstipranks
Trending News
More News >
American Shared Hospital Services (AMS)
:AMS
US Market
Advertisement

American Shared Hospital Services (AMS) AI Stock Analysis

Compare
130 Followers

Top Page

AMS

American Shared Hospital Services

(AMS)

Select Model
Select Model
Select Model
Neutral 51 (OpenAI - 4o)
Rating:51Neutral
Price Target:
$2.00
▼(-3.38% Downside)
American Shared Hospital Services' overall stock score reflects strong revenue growth and strategic expansion, but is weighed down by profitability challenges, negative valuation metrics, and bearish technical indicators. The earnings call provided some optimism with improved margins and growth in new markets, but the net loss and issues in the equipment leasing segment remain concerns.
Positive Factors
Revenue Growth
Consistent revenue growth, particularly from new markets like Puebla, Mexico, indicates expanding market reach and product adoption.
Market Expansion
Expanding into new markets with new facilities supports long-term growth and enhances competitive positioning in the healthcare sector.
Improved Margins
Improved margins reflect better cost management and operational efficiency, contributing to sustainable profitability over time.
Negative Factors
Profitability Challenges
Ongoing net losses highlight profitability challenges, which may hinder long-term financial stability and investment capacity.
Decline in Equipment Leasing
Declining revenue in equipment leasing indicates potential market saturation or competitive pressures, affecting core business segments.
Negative Cash Flow
Negative free cash flow suggests inefficiencies in converting revenue into cash, potentially limiting reinvestment and growth opportunities.

American Shared Hospital Services (AMS) vs. SPDR S&P 500 ETF (SPY)

American Shared Hospital Services Business Overview & Revenue Model

Company DescriptionAmerican Shared Hospital Services (AMS) is a leading provider of advanced medical equipment and services to healthcare facilities across the United States. The company specializes in offering cutting-edge technologies in the field of radiation therapy, particularly in the areas of stereotactic radiosurgery and stereotactic body radiation therapy. AMS partners with hospitals and healthcare organizations to enhance their treatment capabilities, thereby improving patient outcomes and operational efficiencies. The core services include the leasing of medical equipment, providing maintenance and support, and offering training for healthcare personnel.
How the Company Makes MoneyAMS generates revenue primarily through the leasing of advanced medical equipment to hospitals and healthcare facilities. This leasing model allows healthcare providers to access state-of-the-art technology without the burden of high upfront costs. Key revenue streams include monthly lease payments from clients, maintenance contracts for the equipment, and training services for healthcare staff. Additionally, AMS may engage in partnerships with medical technology manufacturers, which can enhance its service offerings and create additional revenue opportunities through shared marketing and sales initiatives. The company’s focus on expanding its client base and maintaining strong relationships with existing customers further contributes to its earnings.

American Shared Hospital Services Earnings Call Summary

Earnings Call Date:Nov 13, 2025
(Q3-2025)
|
% Change Since: |
Next Earnings Date:Apr 02, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted revenue growth, significant improvements in margins, and successful expansion into new markets like Puebla, Mexico. However, challenges remain in the equipment leasing segment and proton therapy volumes, contributing to a net loss for the first nine months. Despite these challenges, the company is optimistic about its growth strategy and future opportunities.
Q3-2025 Updates
Positive Updates
Revenue Growth and Improved Margins
For the third quarter, revenue increased by 2.5% year-over-year, with a 5.6% increase year-to-date. Gross margins improved by 16%, operating loss narrowed with a 92% improvement, and adjusted EBITDA increased by 42% compared to the previous year.
Significant Growth in New Markets
The new radiation therapy treatment center in Puebla, Mexico, reported a 263% annual revenue growth. Additionally, the company saw a 9.4% increase in revenue from its Direct Patient Services segment.
Expansion and New Facilities
Plans to open a Gamma Knife Center in Guadalajara, Mexico, were announced, and the acquisition of three Rhode Island cancer treatment centers is contributing to increased patient consultations and treatment volumes.
Negative Updates
Decline in Equipment Leasing Segment
Revenue from the equipment leasing segment decreased from $11.5 million in the first nine months of 2024 to $9.7 million in the first nine months of 2025. Gamma Knife revenue declined by 4.2% due to contract expirations and lower proton beam radiation therapy volumes.
Decrease in Proton Therapy Volumes
Total proton therapy fractions for Q3 2025 were 3,095, an 18% decrease from 3,764 fractions in the first nine months of 2024, primarily due to cyclical fluctuations.
Net Loss for the First Nine Months
The company reported a net loss of $922,000 for the first nine months of 2025, compared to net income of $3.5 million in the first nine months of 2024, primarily due to the absence of a one-time bargain purchase gain from the previous year.
Company Guidance
During the American Shared Hospital Services third quarter 2025 earnings call, the company reported several key financial metrics and growth initiatives. The revenue for Q3 2025 rose by 2.5% to $7.2 million, driven by a notable 263% increase in revenue from their new radiation therapy center in Puebla, Mexico. The Direct Patient Services segment saw a 9.4% rise in revenue, while the medical equipment leasing segment experienced a decrease. Gross margins improved to 22.1%, with a 60% year-over-year increase to $1.6 million. The company's adjusted EBITDA grew by 42% to $1.9 million. The number of Gamma Knife procedures increased to 231, contributing to a 15.9% rise in revenue from linear accelerator systems. Year-to-date revenues increased by 5.6% to $20.4 million, with significant growth in direct patient care services. The company is focused on strategic initiatives, including the development of new treatment centers in Rhode Island and Mexico, anticipating continued revenue growth and improved profitability.

American Shared Hospital Services Financial Statement Overview

Summary
American Shared Hospital Services shows mixed financial performance. Revenue growth is present, but profitability and cash flow generation are concerning. The balance sheet is stable with low leverage, but negative ROE and cash flow challenges highlight the need for improved operational efficiency.
Income Statement
55
Neutral
The income statement shows a mixed performance. The TTM data reveals a slight revenue growth of 5.1%, but the company is struggling with profitability, as indicated by negative net profit and EBIT margins. The gross profit margin has decreased from previous years, reflecting challenges in maintaining cost efficiency. The revenue growth is positive, but the declining margins and negative net income are concerning.
Balance Sheet
60
Neutral
The balance sheet indicates a relatively low debt-to-equity ratio of 0.15 in the TTM period, suggesting a conservative leverage approach. However, the return on equity is negative, reflecting the company's struggle to generate profits from its equity base. The equity ratio is stable, indicating a solid capital structure, but the negative ROE highlights profitability issues.
Cash Flow
50
Neutral
Cash flow analysis shows a significant challenge with free cash flow, which is negative in the TTM period. Although operating cash flow is positive, the free cash flow to net income ratio is unfavorable, indicating inefficiencies in converting profits into free cash flow. The operating cash flow to net income ratio suggests some stability, but the negative free cash flow growth is a concern.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue29.42M28.34M21.32M19.75M17.63M17.84M
Gross Profit7.35M9.19M9.34M8.38M6.73M4.47M
EBITDA3.81M8.91M6.97M8.44M6.97M-1.43M
Net Income-2.25M2.19M610.00K1.33M194.00K-7.06M
Balance Sheet
Total Assets59.63M60.20M48.16M43.96M45.43M43.65M
Cash, Cash Equivalents and Short-Term Investments5.34M11.03M13.69M12.34M8.14M3.96M
Total Debt24.62M23.23M17.64M14.31M17.47M14.40M
Total Liabilities31.03M30.17M21.88M18.33M21.19M20.00M
Stockholders Equity24.57M25.18M22.62M21.63M19.89M19.27M
Cash Flow
Free Cash Flow-10.20M-7.77M-555.00K6.85M4.59M9.29M
Operating Cash Flow4.08M167.00K5.72M7.24M6.27M9.74M
Investing Cash Flow-13.98M-7.11M-6.27M-388.00K-1.67M-2.39M
Financing Cash Flow1.18M4.41M1.91M-2.66M-655.00K-4.81M

American Shared Hospital Services Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2.07
Price Trends
50DMA
2.31
Negative
100DMA
2.41
Negative
200DMA
2.53
Negative
Market Momentum
MACD
-0.05
Negative
RSI
41.62
Neutral
STOCH
20.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMS, the sentiment is Negative. The current price of 2.07 is below the 20-day moving average (MA) of 2.11, below the 50-day MA of 2.31, and below the 200-day MA of 2.53, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 41.62 is Neutral, neither overbought nor oversold. The STOCH value of 20.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AMS.

American Shared Hospital Services Risk Analysis

American Shared Hospital Services disclosed 20 risk factors in its most recent earnings report. American Shared Hospital Services reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

American Shared Hospital Services Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
$13.69M-5.69-8.75%17.84%-156.13%
44
Neutral
$34.64M10.05%-0.29%94.56%
44
Neutral
$94.55M-17.32%-47.03%-274.41%
41
Neutral
$143.54K-0.70%-2.38%
38
Underperform
$22.84M-1.01-22.38%56.66%
38
Underperform
$60.81M-0.17-257.39%-2.15%-6.72%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AMS
American Shared Hospital Services
2.07
-1.11
-34.91%
CCM
Concord Medical Services
3.87
-0.81
-17.31%
MODVQ
ModivCare
0.01
-18.50
-99.95%
CCEL
Cryo-Cell International
3.98
-4.05
-50.44%
DCGO
DocGo
0.97
-3.32
-77.39%
PIII
P3 Health Partners
5.33
-6.61
-55.36%

American Shared Hospital Services Corporate Events

American Shared Hospital Services’ Earnings Call Highlights Growth and Challenges
Sep 1, 2025

American Shared Hospital Services’ recent earnings call revealed a mixed sentiment, characterized by strong sequential growth in revenue and EBITDA, primarily fueled by strategic expansion in direct patient services and international markets. Despite these positive developments, the company faced challenges such as declines in equipment leasing revenue and treatment volumes, resulting in a net loss. Nevertheless, the company expressed confidence in its long-term growth strategy.

American Shared Hospital Services Sees Revenue Growth in Q2 2025
Aug 14, 2025

American Shared Hospital Services (AMS) is a prominent provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services, operating primarily in North and South America. The company specializes in leasing and direct patient care services, offering integrated cancer care solutions in collaboration with health systems and cancer networks.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 19, 2025